Advertisement
The Scientist
The Scientist

UK Approves Embryonic Stem Cell Trial

The US company investigating the use of human embryonic stem cells to treat a type of macular dystrophy expands its clinical trials to the UK.

By | September 22, 2011

WIKIMEDIA COMMONS, GREYSON ORLANDO

The UK Medicines and Healthcare products Regulatory Agency (MHRA) today (September 22) approved the UK’s first ever human embryonic stem cell (hESC) trial. To be led by eye surgeon James Bainbridge of Moorfields Eye Hospital and University College London, the study will involve 12 patients with Stargardt's macular dystrophy, a progressive vision loss disease for which there is currently no treatment. Patients will receive injections of hES-derived retinal pigment epithelial cells into their eyes as part of the trial.

The Massachusetts-based company, Advanced Cell Technology (ACT), received approval for its US trial from the Food and Drug Administration last year, with the first patient receiving treatment this past July. The company also plans to apply for UK approval for a trial to test the therapy on patients with age-related macular degeneration, ACT Chief Scientific Officer Robert Lanza told ScienceInsider, which is also currently in trials in the United States.

Advertisement
The Scientist
The Scientist

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube
Advertisement

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Culture Techniques
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
NuAire
NuAire

Popular Posts

Advertisement